Publications + Posters

 |  AACR
October 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
 |  AACR
October 2025
APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumors
 |  AACR
October 2025
TNG961: Targeting HBS1L for the Treatment of Chr9p21 Deleted Cancers with FOCAD loss
 |  Botton Champalimaud International Pancreatic Cancer Conference
October 2025
PRMT5: A Precision Therapeutic Target for MTAP-Loss Pancreatic Tumors
Maxim Pimkin
 |  Botton Champalimaud International Pancreatic Cancer Conference
October 2025
TNG961: Targeting HBS1L for the Treatment of Chr9p21 Deleted Cancers with FOCAD loss
Jannik N. Andersen
Learn more about our drug discovery programs and explore our pipeline.Learn more about our drug discovery programs and explore our pipeline.